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Abstract
Background: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of
chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects
on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC).
Methods: Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/
doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat
according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA
damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry.
Results: Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean
erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638
and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological
toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in
CD45 + CD3- cells in non-STF, but not in STF patients.
Conclusions: STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC
patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after
chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible
benefits of STF during chemotherapy.
Trial registration: ClinicalTrials.gov: NCT01304251, March 2011
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Background
Chronic reduction of calorie intake without malnutrition re-
duces spontaneous cancer incidence and delays progression
in a variety of tumors in rodents [1–4]. In long-term calorie
restricted non-human primates, cancer incidence and mortal-
ity are reduced [5], and studies of long-term calorie restricted
human subjects have shown a reduction of metabolic and
hormonal factors associated with cancer risk [6–8]. Chronic
calorie restriction is not practical for clinical use since it
causes unacceptable weight loss in cancer patients [9]. How-
ever, brief periods of fasting may be feasible in patients and,
in mice have been shown to slow cancer growth at least as
effectively as chronic calorie restriction without compromis-
ing bodyweight [10–12]. Even more importantly, the effects
of short-term fasting (STF) on susceptibility to chemotherapy
differ between healthy somatic and cancer cells, a
phenomenon called differential stress resistance (DSR)
[10, 11, 13, 14]. In healthy cells, nutrient deprivation shuts
down pathways promoting growth to invest energy in main-
tenance and repair pathways that contribute to resistance
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to chemotherapy [15, 16]. In contrast, tumor cells are un-
able to activate this protective response due to uncon-
trolled activation of growth pathways by oncogenic
mutations. Indeed, the persistently increased growth rate
of tumor cells requires abundant nutrients, and therefore,
STF renders tumor cells more sensitive to chemotherapy
[10–12]. Hence, STF is a promising strategy to enhance
the efficacy and tolerability of chemotherapy.
In human subjects, STF is safe and well tolerated [17–19].
A case series of 10 patients with various types of cancer
demonstrated that fasting in combination with chemother-
apy is feasible and might reduce chemotherapy-induced side
effects [20]. We conducted a randomized-controlled pilot
trial to identify the effects of 48-h of STF on chemotherapy-
induced side effects and hematologic parameters in breast
cancer (BC) patients, who received TAC (docetaxel, doxo-
rubicin and cyclophosphamide) chemotherapy. Further-
more, we quantified chemotherapy-induced DNA damage
in peripheral blood mononucleated cells (PBMCs) by
measuring γ-H2AX accumulation [21]. Upon induction of
DNA double strand breaks (DSBs), H2AX is rapidly phos-
phorylated at the site of DNA damage [22]. γ-H2AX has
been widely used to quantify DNA damage after irradiation
[23–26], where the expression has been shown to be associ-
ated with healthy tissue damage [22, 27–30]. However, use
of γ-H2AX as a marker for chemotherapy toxicity to
healthy cells is relatively unexplored.
Methods
Patients
All women included in the study had a histologically
confirmed diagnosis of HER2-negative stage II and III BC
and were receiving (neo) adjuvant TAC-chemotherapy
(see below). Eligibility criteria included age ≥ 18 years;
BMI ≥19 kg/m2; WHO performance status 0–2; life ex-
pectancy of >3 months; adequate bone marrow function
(i.e. white blood counts >3.0 × 109/L, absolute neutrophil
count ≥1.5 × 109/l and platelet count ≥ 100 × 109/l);
adequate liver function (i.e. bilirubin ≤1.5 × upper limit of
normal (UNL) range, ALAT and/or ASAT ≤2.5 × UNL,
Alkaline Phosphatase ≤5 × UNL); adequate renal function
(i.e. calculated creatinine clearance ≥50 mL/min);
adequate cardiac function; absence of diabetes mellitus;
absence of pregnancy or current lactation; and written
informed consent. TNM classification system was used to
record stage of disease in accordance with Dutch guide-
lines of clinical practice (http://www.oncoline.nl).
Study design
Patients were randomized in a 1:1 ratio to fast beginning
24 h before and lasting until 24 h after start of chemother-
apy (‘STF’ group) or to eat according to the guidelines for
healthy nutrition with a minimum of two pieces of fruit
per day (‘non-STF’ group). STF subjects were only allowed
to drink water and coffee or tea without sugar. All patients
kept a food diary of the consumption of food and
drinks during the 24 h pre- and post-chemotherapy. All
patients gave informed consent in writing. The study
(NCT01304251) was conducted in accordance with the
Declaration of Helsinki (October 2008) and was ap-
proved by the Ethics Committee of the LUMC in agree-
ment with the Dutch law for medical research involving
human subjects.
Drugs
On the first day of each 3-weekly cycle (six in total),
women received TAC (docetaxel 75 mg/m2 IV for 1 h,
adriamycin 50 mg/m2 IV for 15 min and cyclophospha-
mide 500 mg/m2 IV for 1 h) with granulocyte-colony
stimulating factor (G-CSF; pegfilgrastim 6 mg) support
the day after chemotherapy administration. Patients
received prophylactic dexamethasone (8 mg, BID the
day before, the day of and the day after chemotherapy
administration) in order to prevent fluid retention and
hypersensitivity reactions. The anti-emetic agent granise-
tron (serotonin 5-HT3 receptor antagonist; 1 mg) was
administered prior to chemotherapy infusion.
Blood sampling
Venous blood samples were drawn before randomization,
at a maximum of 2 weeks prior to treatment (baseline)
and directly before each chemotherapy administration
(pre-chemotherapy, day 0). Non-fasting blood samples
were drawn from subjects in the non-STF group. The
effect of fasting was determined by recording 1) metabolic
parameters (insulin, glucose, insulin growth factor 1
(IGF-1), insulin growth factor binding protein 3 (IGF-
BP3)); 2) endocrine parameters (thyroid-stimulating
hormone (TSH), triiodothyronine (T3) and free thyroxine
(FT4)); 3) hematologic parameters (erythrocyte-, thrombo-
cytes- and leukocyte count) and 4) inflammatory response
(C-Reactive Protein (CRP)). For measurement of meta-
bolic, endocrine and inflammatory parameters , blood was
collected in a serum-separating tube and for hematologic
parameters, blood was collected in an EDTA tube. In
addition, hematologic parameters and CRP were mea-
sured on day 7 after each chemotherapy cycle. All sam-
ples were analyzed by the accredited clinical laboratory
of the LUMC.
To investigate the effect of STF on chemotherapy-
induced DNA damage in PBMCs, heparinized venous
blood samples (9 mL) were collected for both patient
groups during each cycle just prior to chemotherapy,
for some patients at 30 min after completion of chemo-
therapy, and on day 7 after administration. Samples were
stored at room temperature until processing (in most
cases directly after withdrawal or at least within 24 h).
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Toxicity
During each cycle, patients were instructed to report the
experienced side effects, graded as mild, moderate or se-
vere. Self-reported side effects, side effects documented
by the physician and hematological toxicity were graded
according to the Common Terminology Criteria for
Adverse Events version 4.03 (CTCAE v.4.03) [31].
Isolation of PBMCs and γ-H2AX staining
PBMCs were isolated using Ficoll Paque Plus (GE Health-
care, Uppsala, Sweden) according to the manufacturer’s
instructions. Isolated PBMCs were carefully resuspended
in 1 ml of Dulbecco’s Modified Eagle Medium (DMEM;
Gibco) supplemented with 40 % fetal bovine serum (FBS;
PAA Laboratories GmbH, Pasching, Austria) and 10 % di-
methyl sulfoxide (DMSO) and divided over two cryovials.
Samples were directly transferred to an isopropanol cham-
ber and incubated at −80 °C for a minimum of 24 h to
cryopreserve before they were stored in the vapor phase of
liquid nitrogen.
Samples were processed batch wise, so that samples
from distinct time points within each cycle were processed
simultaneously for each patient. After thawing in RPMI at
room temperature, PBMCs were fixed in 1.5 % formalde-
hyde and permealized in ice-cold methanol. Cells were
washed 3 times in staining buffer (PBS with 5 % bovine
serum albumin (BSA, Sigma)) and stained for 30 min on
ice with anti-CD45-PerCP-Cy5.5 (1:20, BD, clone 2D1),
anti-CD3-PE (1:10, BD, clone SK7), anti-CD14-AF700
(1:80, BD, clone M5E2), anti-CD15-PE CF594 (1:100, BD,
clone W6D3) and anti-γ-H2AX-AF488 (1:100, Biolegend,
clone 2F3), followed by another washing step. The cell
acquisition was performed immediately after the staining
procedure (BD LSR Fortessa Flow Cytometer analyzer, BD
Bioscience, Breda, The Netherlands) and data was ana-
lyzed using BD FACS Diva Software version 6.2. Compen-
sations were set using a mixture of anti-mouse Ig/negative
control beads (BD). The CD45+ cells were gated, after
which the CD3+ T lymphocytes, CD3- myeloid cells (also
harboring B lymphocytes) or CD14 + CD15- monocytes
were analyzed for the geomean (as measure for the
intensity) of γ-H2AX.
Statistical analysis
All parameters were tested for normality using a
Kolmogorov-Smirnov test, with Bonferroni adjustment
when evaluated in subgroups. Normality distributed
parameters, if necessary after log transformation, were
summarized as mean (and standard error (SE)) and
compared using an independent samples t-test for in-
dependent groups or paired t-test for paired groups.
The non-normally distributed parameters were summa-
rized as median (and range) and compared using a
Mann–Whitney test for independent groups or Wilcoxon
signed rank test for paired groups. Data of different pa-
tients and different cycles were combined to test differ-
ences between time points and treatment groups. All tests
were 2-tailed with a significance level of 0.05. All data
were analyzed using IBM SPSS Statistics for Windows
(Version 20.0. Armonk, NY: IBM Corp).
Results
Patient characteristics
From May 2011 until December 2012, thirteen women
with early BC were included and randomized into the
STF (n = 7) or non-STF group (n = 6). Patient character-
istics are summarized in Table 1. In the STF arm, 42.9 %
of the patients had stage III disease compared to 16.7 %
of patients in the non-STF arm. Estrogen receptor status
was negative for one patient in the STF group (14.3 %)
and half of the patients in the non-STF group. Three pa-
tients had a Bloom-Richardson grade III tumor in the
STF group and one in the non-STF group. One patient
could not be graded due to the neoadjuvant chemother-
apy. None of these patient characteristics was signifi-
cantly different between the two groups.
Patients were motivated to fast and the STF was well
tolerated. Two patients in the STF arm withdrew from
fasting after the third chemotherapy cycle: one due to
pyrosis and one due to recurrent febrile neutropenia. In
both patients, the side effects persisted on a normal diet
during cycles 4–6. All patients finished 6 cycles of TAC.
There were no significant differences in chemotherapy-
related adjustments between the two groups.
Toxicity
The most frequently observed side effects, were grade I/II
and the percentage of occurrence of each side effect is re-
corded in Table 2. No significant differences were observed
between the two patient groups. The total incidence of
grade III/IV side effects that occurred in both groups is
given in Table 2. The observed grade III/IV side effects
were neutropenic fever, fatigue and infection (pneumonia
and neutropenic enterocolitis (typhlitis)). There was no sig-
nificant difference in incidence of grade III/IV side effects
between the STF and non-STF group. No grade V toxicity
occurred during the chemotherapy in either group.
Metabolic, endocrine and inflammatory parameters
Metabolic and endocrine parameters at randomization
(maximum 2 weeks before first chemotherapy cycle) and
the mean or median (depending on distribution) of the
day 0 values (immediately before chemotherapy infusion,
when patients in the STF group had fasted for 24 h)
were compared (Table 3). As no baseline values were
available for three patients, no paired t-test could be
performed, hence the deviating N values. In the STF
and non-STF groups, median blood glucose values
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were significantly increased between the two time
points (P = 0.042 and P = 0.043, respectively). There
was no significant difference in median insulin level be-
tween the two time points in the STF group, but in the
non-STF group, the insulin level was significantly increased
(P = 0.043). Mean IGF-1 levels were significantly decreased
(P = 0.012) in the STF group; no change was observed in
the non-STF group. IGF-BP3 levels did not change in ei-
ther group. TSH was significantly reduced (P = 0.034) in
the non-STF group, but not in the STF group. The FT4
did not change significantly over time in patients in either
group.
Figure 1 shows the mean, log transformation of the mean
or the median (dependent of the distribution) of day 0
metabolic, endocrine and inflammatory parameters of all
cycles compared between STF and non-STF subjects. The
FT4 levels were significantly higher (P = 0.034, 95 % CI
0.08–1.91) in the STF group compared to the non-STF
group. Glucose and insulin levels appeared to be lower in
the STF group compared to the non-STF group, but the
difference was not statistically significant. IGF-1, IGF-BP3,
TSH and T3 showed similar levels in STF and non-STF
patients.
Hematologic parameters
Hematologic parameters measured on day 0 (i.e., immedi-
ately before chemotherapy infusion, when the STF group
had fasted for 24 h), were similar in the two groups.
Erythrocyte counts were significantly higher in the STF
group during chemotherapy treatment at day 7 (P = 0.007,
95 % CI 0.106–0.638) and at day 21 (P = 0.002, 95 % CI
0.121–0.506) compared to the control group (Fig. 2).
Thrombocyte counts were only significantly higher at day
7 (P = 0.00007, 95 % CI 38.7–104) in the STF arm com-
pared to the non-STF arm. For leukocytes and neutro-
phils, no significant difference in counts was observed,
both at day 7 and day 21 between STF and non-STF pa-
tients (not shown).
Table 2 Grade I/II and grade III/IV toxicity during 6 cycles of
TAC in both groups
Grade I/II
STF Non-STF
Fatigue 5 (71 %) 6 (100 %)
Infection 3 (43 %) 1 (17 %)
Mucositis 4 (57 %) 4 (67 %)
Neuropathy 5 (71 %) 3 (50 %)
Diarrhea 5 (71 %) 2 (33 %)
Dizziness 3 (43 %) 3 (50 %)
Nausea 7 (100 %) 4 (67 %)
Eye complaints 4 (57 %) 2 (33 %)
Constipation 4 (57 %) 2 (33 %)
Grade III/IV
Total 6 3
Neutropenic fever 2 (29 %) 2 (33 %)
Fatigue 2 (29 %) 0 (0 %)
Infection 2 (29 %) 1 (17 %)
All side effects were scored according CTCAE4.03. Each side effect was scored maximal
once per patient during the course (the highest grade of occurrence was scored)
STF short-term fasting
Table 1 Patient characteristics
STF Non-STF P Value
(n = 7) (n = 6)
Median Age (range), Years 51 (47–64) 52 (44–69) 1.00
Median Body Mass Index (SEM), kg/m2 25.5 (3.3) 23.8 (2.4) 0.53
WHO-status
Grade 0 6 (85.7 %) 6 (100 %) 0.34
Grade 1 1 (14.3 %) 0 (0.0 %)
Treatment
Adjuvant 5 (71.4 %) 3 (50.0 %) 0.43
Neo-adjuvant 2 (28.6 %) 3 (50.0 %)
T-classification
T1 3 (42.9 %) 2 (33.3 %) 0.94
T2 3 (42.9 %) 3 (50.0 %)
T3 1 (14.3 %) 1 (16.7 %)
N-classification
N0 2 (28.6 %) 2 (33.3 %) 0.85
N+ 5 (71.4 %) 4 (66.7 %)
Stage
II 4 (57.2 %) 5 (83.3 %) 0.31
III 3 (42.9 %) 1 (16.7 %)
ER-status
ER- 1 (14.3 %) 3 (50.0 %) 0.16
ER+ 6 (85.7 %) 3 (50.0 %)
PR-status
PR- 3 (42.9 %) 4 (66.7 %) 0.39
PR+ 4 (57.1 %) 2 (33.3 %)
Grade (BR)
1 1 (14.3 %) 1 (16.7 %) 0.44
2 2 (28.6 %) 4 (66.7 %)
3 3 (42.9 %) 1 (16.7 %)
Unknown 1 (14.3 %) 0 (0.0 %)
Chemotherapy related adjustment
No 3 (42.9 %) 3 (50.0 %) 0.80
Yes 4 (57.1 %) 3 (50.0 %)
STF short-term fasting, SEM standard error of the mean, ER estrogen receptor;
PR progesterone receptor, BR Bloom-Richardson
de Groot et al. BMC Cancer  (2015) 15:652 Page 4 of 9
DNA damage in PBMCs
No cumulative effect on DNA damage of chemotherapy
was seen during the 6 cycles of TAC in CD45 + CD3+
lymphocytes, CD45 + CD14 + CD15- monocytes and
CD45 + CD3- myeloid cells as no significant differences
in γ-H2AX intensity were seen throughout 6 cycles, (see
Additional file 1). Therefore, the measured γ-H2AX
intensity from each cycle at the same time point (before
chemotherapy, after 30 min, and after 7 days) was com-
bined for analysis. The level of γ-H2AX intensity (given
as geomean) measured by flow cytometry in CD45 +
CD3+ lymphocytes, CD45 + CD14 + CD15- monocytes
and CD45 + CD3- myeloid cells are given in Table 4.
γ-H2AX intensity was increased after chemotherapy
infusion in the CD45 + CD3+ lymphocytes 30 min after
chemotherapy infusion in both groups and in the
non-STF group after 7 days as well. In the CD45 +
CD14 + CD15- monocytes no difference in γ-H2AX
intensity was seen after 30 min, but after 7 days, a
significant increase was seen in both groups. In the
CD45 + CD3- myeloid cells, a significantly increase
was seen in γ-H2AX intensity at 30 min post-
chemotherapy only in the non-STF group. γ-H2AX
intensity was consistently higher in CD45 + CD14 +
CD15- monocytes than in CD45 + CD3+ lymphocytes
and CD45 + CD3- myeloid cells.
Discussion
This is the first randomized pilot study to explore the ef-
fects of 48 h STF on the side effects of chemotherapy in
early BC patients. Only one study to date [20] has
examined the effects of fasting on chemotherapy-induced
side effects in cancer patients, but therein the patients
served as their own controls and had various tumor types
and treatment protocols. The main findings of our study
were that STF was well-tolerated, safe and had beneficial
effects on hematologic toxicity and possibly on DNA
damage in healthy cells (lymphocytes and myeloid cells).
Although STF was well tolerated, two patients withdrew
from STF after 3 cycles of chemotherapy after experien-
cing a side effect (pyrosis and recurrent febrile neutro-
penia, respectively). Since these side effects persisted in
both patients during the subsequent 3 cycles of chemo-
therapy without STF, they may not be related to STF. All
patients finished their treatment schedule of 6 cycles of
TAC and no significant difference in occurrence of
chemotherapy-related adjustments were found between
the two groups. The side effect profile of the TAC proto-
col seen in this study was consistent with the existing
literature [32–34]. STF had no beneficial effect on patient-
reported side effects in this study. This may be explained
by the large variability of side effects between patients,
which may be attributable to occurrence of symptom
clusters and pharmacogenomics [35, 36]. This may have
masked any beneficial effects of STF. Additionally, the
relatively short period of fasting (48 h) may explain the
lack of benefit in terms of side effects: previous studies
have shown that a longer fasting period is required to
cause major changes in IGF-1 levels [20, 37]. Reduction
of plasma IGF-1 levels is a critical mediator of differ-
ential stress resistance in response to nutrient restric-
tion (see below).
Table 3 Metabolic and endocrine parameters at baseline (before randomization) and day 0 (immediately before chemotherapy
infusion during the use of prophylactic dexamethasone)
Parameter N Baseline Median (range) Day 0 (with DEX) Median (range) In/decrease P value
Glucose (3.1-6.4 mmol/L) STF (n = 5) 5.2 (4.3-5.5) 6.8 (5.6-9.0) ↑ 0.042
Non-STF (n = 5) 4.8 (4.7-6.7) 7.0 (6.1-8.8) ↑ 0.043
Insulin (0-20 mU/L) STF (n = 5) 14.0 (2.0-40.0) 13.0 (6.0-36.0) = 0.500
Non-STF (n = 5) 2.0 (2.0-9.0) 16.0 (9.0-63.0) ↑ 0.043
Parameter N Baseline Mean (SE) Day 0 (with DEX) Mean (SE) In/decrease P value
IGF-1 (5.4-24.3 nmol/L) STF (n = 4) 23.7 (2.9) 19.6 (3.3) ↓ 0.012
Non-STF (n = 5) 17.5 (3.5) 16.8 (2.8) = 0.634
IGF-BP3 (2.2-5.8 mg/L) STF (n = 4) 5.0 (0.5) 4.2 (0.3) = 0.212
Non-STF (n = 5) 4.5 (0.2) 3.9 (0.3) = 0.122
TSH (0.3-4.8 mU/L) STF (n = 3) 1.38 (0.26) 0.61 (0.08) = 0,065
Non-STF (n = 5) 1.49 (0.14) 0.42 (0.06) ↓ 0.034
FT4 (12-22pmol/L) STF (n = 3) 15.4 (0.92) 13.9 (0.94) = 0.117
Non-STF (n = 5) 15.0 (0.54) 14.0 (0.34) = 0.149
Bold value indicates that p < 0.05
DEX dexamethasone, IGF-1 Insulin-like growth factor 1, IGF-BP3 insulin- like growth factor binding protein 3, TSH thyroid-stimulating hormone; FT4 free thyroxine,
STF short-term fasting, SE standard error
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γ-H2AX phosphorylation indicates the presence of
double-strand DNA breaks and could serve as a marker
for chemotherapy toxicity in healthy cells, as seen in a
phase I/II trial with patients treated with chemotherapy
and belinostat [38]. We measured the induction of
chemotherapy-induced DNA damage in PBMCs by
phosphorylation of H2AX (i.e. γ-H2AX). The level of γ-
H2AX in CD45 + CD3+ lymphocytes was increased
after 30 min in both groups. After 7 days, γ-H2AX ac-
cumulation remained increased in the non-STF group
only, suggesting that STF promotes the recovery of
chemotherapy-induced DNA damage in these cells. In
CD45 + CD3- myeloid cells, the level of γ-H2AX was in-
creased after 30 min in the non-STF group, but not in
the STF group, suggesting STF protected these cells
against the induction of DNA damage by chemotherapy.
As these myeloid cells may harbor the antigen-
presenting cells required for induction of an effective
anti-tumor immune response, this result warrants fur-
ther study [39]. Moreover, the relation of this finding
with the clinical benefit of STF still needs to be
established.
Fig. 1 Metabolic, endocrine and inflammatory parameters on day 0 compared between STF and non-STF subjects. Values are measured on day 0
immediately before chemotherapy infusion (during the use of prophylactic dexamethasone). Mean values of different patients of different cycles (1–6)
are combined to test differences between both treatment groups. * P value <0.05. Reference values: glucose 3.1-6.4 mmol/L; insulin 0-20 mU/L; IGF-1
5.4-24.3 nmol/L; IGF-BP3 2.2-5.8 mg/L; TSH 0.3-4.8 mU/L; FT412-22pmol/L, T31.1-3.1 nmol/L; CRP 0.0-5.0 mg/L;. IGF-1; Abbreviations: STF: short-term
fasting, IGF-1:Insulin-like growth factor 1, IGF-BP3: insulin- like growth factor binding protein 3, TSH: thyroid-stimulating hormone; FT4:,free thyroxine; T3:
CRP; C-reactive protein
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The significantly higher erythrocyte and thrombocyte
counts observed after chemotherapy in the STF group
could be explained by decreased breakdown of circulating
cells and/or less severe bone marrow suppression. This
supports the hypothesis that STF may protect against
chemotherapy-associated hematological toxicity. No sig-
nificant difference in leukocyte and neutrophil counts was
seen. This could be explained by the use of pegfilgrastim,
which acts to increase the production of white blood cells
in bone marrow and may therefore prevent a decrease in
leukocyte counts in response to chemotherapy.
Plasma glucose levels increased and insulin levels
remained constant in response to STF. The use of
dexamethasone may explain this phenomenon [40–42].
Dexamethasone was administered for anti-emesis, reduc-
tion of fluid retention and dampening of hypersensitivity
reactions in response to docetaxel [43]. However, the meta-
bolic effects of dexamethasone may have attenuated the
benefits of STF. In the absence of dexamethasone, STF re-
duces circulating glucose, insulin and IGF-1 levels [19, 44].
A decrease in IGF-1 affects other factors (e.g. Akt, Ras and
mammalian target of rapamycin (mTOR)) to down-
regulate cell growth and proliferation [45–47]. Reduction
of IGF-1 is one of the key mediators of the protective
effects of STF in healthy cells [44]. Although fasting
modestly reduced plasma IGF-1 concentrations in the
current trial, the concomitant use of dexamethasone
probably attenuated the decline and thereby probably
counteracted the beneficial impact of the dietary
intervention.
Our study has some limitations. The most obvious limita-
tion of our study is the small sample size, which may have
Fig. 2 Hematologic parameters compared between both groups. Values are measured on day 0 of cycle 1 immediately before the chemotherapy
infusion, on day 7 of cycle 1–5 combined and day 21 of cycle 1–5 combined. * P value <0.05. STF; short-term fasting, Reference values: erythrocytes
4-5*1012/L; thrombocytes 150-400*109/L
Table 4 γ-H2AX intensity in CD45 + CD3+ lymphocytes, CD45 + CD14 + CD15- monocytes and CD45 + CD3-myeloid cells
Parameter N Before CT Day 0 Mean (SE) 30 minutes after CT Day 0 Mean (SE) Increase P value
CD45 + CD3+ lymphocytes STF (n = 14) 75.5 (4.7) 89.5 (6.5) ↑ 0.020
Non-STF (n = 6) 78.8 (5.6) 95.7 (5.9) ↑ 0.001
CD45 + CD14 + CD15- monocytes STF (n = 12) 162.2 (11.9) 192.5 (14.3) = 0.055
Non-STF (n = 6) 180.8 (15.6) 206.2 (20.8) = 0.051
CD45 + CD13- myeloid cells STF (n =14) 104.0 (7.0) 109.5 (8.4) = 0.594
Non-STF (n = 6) 109.0 (7.8) 123.0 (6.7) ↑ 0.009
Parameter N Before CT Day 0 Median (range) 7 days after CT Median (range) Increase P value
CD45 + CD3+ lymphocytes STF (n =16) 75.5 (49–157) 83.0 (64–141) = 0.109
Non-STF (n = 9) 78.0 (47–102) 90.0 (71–114) ↑ 0.015
CD45 + CD14 + CD15- monocytes STF (n = 14) 157.0 (114–231) 186.5 (132–295) ↑ 0.035
Non-STF (n = 8) 203.5 (116–273) 258.5 (183–319) ↑ 0.021
CD45 + CD13- myeloid cells STF (n = 16) 106.0 (71–173) 84.0 (65–145) = 0.379
Non-STF (n = 9) 88.0 (49–137) 88.0 (74–119) = 0.477
Paired comparison between pre- and post- chemotherapy (30 minutes and 7 days; median of 6 cycles of TAC) for the different cell types. γ-H2AX intensity is given
as mean and median depending on the distribution
Bold value indicates that p < 0.05. 95 % CI; 95 % confidence interval. P values are given for differences of intensity of γ-H2AX between pre-
and post-chemotherapy
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limited the power of the study and precludes firm statistical
conclusions. Moreover, as high dose dexamethasone in-
duces insulin resistance, compensatory hyperinsulinemia
and hyperglycemia, its prophylactic use may have counter-
acted the beneficial effects of STF. Therefore the use of this
drug warrants further study for future clinical trials with
STF. Finally, as DNA damage is repaired rapidly [48], our
protocol may not be rapid enough to obtain a reliable
quantification. Therefore, a consistent and rapid protocol
for the isolation and fixation of PBMCs immediately after
blood withdrawal should be applied in future studies to
allow for reliable quantification of damage induced by
chemotherapy.
Larger randomized trials such as the DIRECT study
(NCT02126449) are now ongoing to evaluate the impact of
STF on tolerance to and efficacy of neoadjuvant chemo-
therapy in women with stage II or III BC. Because it is
likely that the positive effects of STF will be enhanced if the
period of fasting is prolonged [37, 49], a very low calorie,
low protein fasting mimicking diet (FMD) is used to ease
the burden of prolonged fasting [50]. Prophylactic dexa-
methasone will be omitted in the FMD arm during the first
4 chemotherapy cycles to reduce its potentially counter-
active metabolic effects. Moreover, blood will be processed
immediately after sampling to prevent potential recovery of
DNA damage.
Conclusions
We demonstrate for the first time that STF is feasible for a
period of 48 h during chemotherapy in a homogeneous
group of patients with early breast cancer. This study pro-
vides evidence that STF attenuates bone marrow toxicity in
these patients and reduces chemotherapy-induced DNA
damage in PBMCs and/or accelerate its recovery. A larger
trial with a longer fasting period is ongoing to investigate
the possible benefits of STF during chemotherapy.
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